Você procurou por: adenocarcinoma (Inglês - Estoniano)

adenocarcinoma
adenokartsinoom

non-adenocarcinoma
mitte-adenokartsinoom

gastric adenocarcinoma
mao adenokartsinoom

adenocarcinoma (n = 847)
adenokartsinoom (n = 847)

non-adenocarcinoma female
adenokartsinoom mitteadenokartsinoom naine

dose adjustments during treatment of pancreatic adenocarcinoma
annuse kohandamine pankrease adenokartsinoomi ravi käigus

the vast majority of patients had adenocarcinoma (92.1%).
valdaval enamikul esines adenokartsinoom (92,1%).

efficacy of docetaxel in the treatment of patients with gastric adenocarcinoma
dotsetakseeli efektiivsus mao adenokartsinoomi ravis

table 1: dose level reductions for patients with pancreatic adenocarcinoma
tabel 1: annuse taseme vähendamine pankrease adenokartsinoomiga patsientidel

gastric cancer and gastro-oesophageal junction (gej) adenocarcinoma
maovähk või gastroösofageaal-liidese adenokartsinoom

(5) progression of pre-existing pancreatic adenocarcinoma with kras mutation.
(5) olemasoleva kras mutatsiooniga pankrease adenokartsinoomi progresseerumine.

chronic myelomonocytic leukaemia(2)(4), pancreatic adenocarcinoma(5)
krooniline müelomonotsütaarne leukeemia(2)(4), pankrease adenokartsinoom(5)

in metastatic adenocarcinoma of the pancreas, abraxane was shown to improve overall survival.
pankrease metastaatilise adenokartsinoomiga patsientidel suurendas abraxane üldist elulemust.

29 adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for metastatic disease.
dotsetakseeli efektiivsust ja ohutust metastaatilise mao adenokartsinoomi, sh gastroösofageaalliidese adenokartsinoomi ravis patsientidel, kes ei olnud varem saanud kemoteraapiat metastaatilise haiguse raviks, hinnati paljukeskuselises avatud randomiseeritud uuringus.

docetaxel 75 mg/m² in combination with cisplatin and 5-fluorouracil for gastric adenocarcinoma cancer
dotsetakseel 75 mg/m2, kombinatsioonis tsisplatiini ja 5-fluorouratsiiliga mao adenokartsinoomi raviks

20 taxotere 75 mg/ m² in combination with cisplatin and 5-fluorouracil for gastric adenocarcinoma cancer
20 taxotere 75 mg/ m2 kombinatsioonis tsisplatiini ja 5– fluorouratsiiliga mao adenokartsinoomi raviks:

20 docetaxel winthrop 75 mg/ m² in combination with cisplatin and 5-fluorouracil for gastric adenocarcinoma cancer
20 docetaxel winthrop 75 mg/ m2 kombinatsioonis tsisplatiini ja 5– fluorouratsiiliga mao adenokartsinoomi raviks:

5.8 % of the adenocarcinoma patients entered the study with locally recurrent disease stage as had been evaluated at baseline.
5,8% adenokartsinoomiga patsientidest kaasati uuringusse uuringu alguses määratud paikselt retsidiveerunud haiguse staadiumis.

description of selected adverse reactions in gastric adenocarcinoma cancer for docetaxel 75 mg/m2 in combination with cisplatin and 5-fluorouracil
kõrvaltoimete valikuline kirjeldus mao adenokartsinoomi kombinatsioonravi korral dotsetakseeliga annuses 75 mg/ m² ning tsisplatiini ja 5-fluorouratsiiliga

diarrhoea occurred in 43.4 % (≥ grade 3: 6.3 %) of adenocarcinoma patients in the nintedanib arm.
kõhulahtisus esines nintedaniibi rühmas 43,4% (≥ 3. astme kõhulahtisust 6,3%) adenokartsinoomiga patsientidest.